Guerbet SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0000032526
EUR
13.40
-0.3 (-2.19%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

High Debt Company with a Debt to Equity ratio (avg) at times

  • Poor long term growth as Net Sales has grown by an annual rate of 0.75% and Operating profit at -12.05% over the last 5 years
  • High Debt Company with a Debt to Equity ratio (avg) at times
  • The company has been able to generate a Return on Capital Employed (avg) of 4.67% signifying low profitability per unit of total capital (equity and debt)
2

Negative results in Dec 24

3

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 226 Million ()

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.90

stock-summary
Return on Equity

0.00%

stock-summary
Price to Book

0.60

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-31.91%
0%
-31.91%
6 Months
-38.95%
0%
-38.95%
1 Year
-44.86%
0%
-44.86%
2 Years
-28.8%
0%
-28.8%
3 Years
-15.4%
0%
-15.4%
4 Years
-62.62%
0%
-62.62%
5 Years
-57.19%
0%
-57.19%

Guerbet SA for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0.75%
EBIT Growth (5y)
-12.05%
EBIT to Interest (avg)
2.20
Debt to EBITDA (avg)
2.80
Net Debt to Equity (avg)
0.84
Sales to Capital Employed (avg)
1.04
Tax Ratio
30.40%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.67%
ROE (avg)
4.44%
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
0.47
EV to EBIT
NA
EV to EBITDA
EV to Capital Employed
0.72
EV to Sales
2.44
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
ROE (Latest)
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
Bullish
Bullish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Guerbet SA"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 7.05% vs 4.30% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -39.19% vs 154.01% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "841.10",
          "val2": "785.70",
          "chgp": "7.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "104.10",
          "val2": "93.60",
          "chgp": "11.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "20.50",
          "val2": "10.60",
          "chgp": "93.40%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.00",
          "val2": "1.90",
          "chgp": "-205.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "13.50",
          "val2": "22.20",
          "chgp": "-39.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "50.90%",
          "val2": "41.30%",
          "chgp": "0.96%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
841.10
785.70
7.05%
Operating Profit (PBDIT) excl Other Income
104.10
93.60
11.22%
Interest
20.50
10.60
93.40%
Exceptional Items
-2.00
1.90
-205.26%
Consolidate Net Profit
13.50
22.20
-39.19%
Operating Profit Margin (Excl OI)
50.90%
41.30%
0.96%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 7.05% vs 4.30% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -39.19% vs 154.01% in Dec 2023

stock-summaryCompany CV
About Guerbet SA stock-summary
stock-summary
Guerbet SA
Pharmaceuticals & Biotechnology
Guerbet SA is a France-based pharmaceutical group specialized in the manufacture and marketing of medical imaging contrast agents destined for diagnostic purposes. It produces medical imaging contrast products for x-ray imaging, magnetic resonance imaging (MRI), ultrasound imaging and for nuclear medicine. The contrast agents are used in the diagnosis of cardio-vascular, inflammatory and neuro-degenerative disorders. The Company’s portfolio of products comprises brands, such as Xenetix, Hexabrix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol, among others. Guerbet SA is also active in the fine chemicals industry through its Simafex subsidiary. The Company operates through its subsidiaries, including Simafex, Medex, SCI KALB, Guerbet LLC, Guerbet Asie Pacifique and Guerbet GmbH, among others.
Company Coordinates stock-summary
Company Details
15 rue des Vanesses, Zone Paris Nord II , VILLEPINTE None : 93420
stock-summary
Tel: 33 1 45915000
stock-summary
Registrar Details